English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Acute kidney injury (AKI) and electrolyte disturbances are the most common manifestations of kidney disease in patients with malignancy in a hospital setting and they are associated with high morbidity and mortality. Kidney failure alters target drug doses, compromising the success of anticancer treatments1. Renal disease also limits access to some types of therapies and excludes patients from clinical trials.

In-hospital and one-year mortality among patients with acute kidney injury and hematological malignancies